Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic ...
FORMER Bristol City star Marvin Brown has been diagnosed with terminal cancer. The 42-year-old came through the youth ranks ...
A fundraiser has raised upwards of £45,000 in support of a former footballer who is receiving end-of-life care. Marvin Brown holds the record for being Bristol City's youngest player. After making his ...
ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today ...
Detailed price information for Esperion Theraptc (ESPR-Q) from The Globe and Mail including charting and trades.
A Selkirk woman living with a disability says she’s spent more than a year fighting Manitoba’s income support system over ...
Given the unmet need of fatigue in primary biliary cholangitis (PBC), the PBC working group of the European Reference Network for Rare Liver Diseases assessed and summarised the current evidence ...
PSC, a chronic liver disease characterized by inflammation and scarring of the bile ducts, is frequently seen alongside IBD, ...
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
The largest phase 3 trial aimed at relieving cholestatic pruritus in PBC shows significantly reduced itching and improved sleep, offering new hope for patients whose symptoms persist.
Nail clubbing, characterized by rounded, thickened, and downward-curved nails, serves as a subtle yet significant indicator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback